PARP1 and neoplasm: The presence of HMGA2 enhanced DNA damage‐induced PARP1 activation (Fig. 1), suggesting that higher concentrations of PARP1 inhibitor olaparib may be required to block PARP1 activity in HMGA2 expressing tumor cells.